-
Mashup Score: 39Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity - 3 day(s) ago
Bone Marrow Transplantation – Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 39Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity - 3 day(s) ago
Bone Marrow Transplantation – Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🎉 New publication in @BMTjournal from my group @fredhutch in collaboration with @RShouval @MSKCancerCenter! https://t.co/3yGjv8W3Nz Ordinal scales have immense value but can be very labor-intensive when manual grading is needed. To address this issue, we repurposed the… https://t.co/wpTKF1Jktf https://t.co/yqsbDhMrRo
-
-
Mashup Score: 101
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with relapsed or refractory CLL or SLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with median duration of CR not reached, along with an established safety profile Breyanzi is now FDA approved for relapsed or refractory large B-cell lymphoma and CLL or SLL, bringing this differentiated CD19-directed CAR T cell therapy to more patients Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 100
Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care In TRANSCEND CLL 004, the first pivotal multicenter trial to evaluate a CAR T cell therapy in patients with relapsed or refractory CLL or SLL, 20% of patients treated with Breyanzi achieved a complete response (CR) with median duration of CR not reached, along with an established safety profile Breyanzi is now FDA approved for relapsed or refractory large B-cell lymphoma and CLL or SLL, bringing this differentiated CD19-directed CAR T cell therapy to more patients Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory
Source: news.bms.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians - Bone Marrow Transplantation - 2 month(s) ago
We are pleased to add this typescript to the Bone Marrow Transplantation Statistics Series. We realize the term cubic splines may be a bit off-putting to some readers, but stay with us and don’t get lost in polynomial equations. What the authors describe is important conceptually and in practice. Have you ever tried to buy a new pair of hiking boots? Getting the correct fit is critical; shoes…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48LinkedIn - 2 month(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: General Medicine News, Hem/OncsTweet-
Proud of Dr. @NGazeau14 who received today the 2023 Robert Korngold Award for the Best Clinical Science article published in @ASTCT_Journal Link to the publication: https://t.co/RBO3HcBvux Congrats again Nicolas and thanks to all collaborators! #Tandem24 @ASTCT Photo credit:… https://t.co/flIV2ZcPfJ https://t.co/5xoQEZGq2Z
-
-
Mashup Score: 29FDA wants classwide boxed warning on all commercial CAR-T therapies amid secondary cancer safety probe - 3 month(s) ago
As many have feared, the FDA’s investigation into secondary T-cell cancers following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. | As many have feared, the FDA’s investigation into secondary T-cell malignancies following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 93FDA Investigating Serious Risk of T-cell Malignancy - 3 month(s) ago
FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27Inappropriate use of statistical power - Bone Marrow Transplantation - 4 month(s) ago
We are pleased to add this typescript, Inappropriate use of statistical power by Raphael Fraser to the BONE MARROW TRANSPLANTATION Statistics Series. The authour discusses how we sometimes misuse statistical analyses after a study is completed and analyzed to explain the results. The most egregious example is post hoc power calculations. When the conclusion of an observational study or clinical…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Disclosures. Shadman:Fate Therapeutics: Consultancy; Genmab: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Bristol Myers Squibb: Consul
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
🎉 New publication in @BMTjournal from my group @fredhutch in collaboration with @RShouval @MSKCancerCenter! https://t.co/3yGjv8W3Nz Ordinal scales have immense value but can be very labor-intensive when manual grading is needed. To address this issue, we repurposed the… https://t.co/wpTKF1Jktf https://t.co/yqsbDhMrRo